# Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

> **NCT02268383** · PHASE2 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 75 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT02268383
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-09
- **Primary completion:** 2020-03-19
- **Final completion:** 2020-03-19
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268383, "Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02268383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*